Telo Genomics Corp (TSE:TELO) has released an update.
Telo Genomics Corp. has received approval from the Intellectual Property Ontario Program, potentially securing up to CAD 80,000 for their IP costs. This support will bolster Telo’s growing patent portfolio, which includes technologies like the TeloViewSMM test for smoldering multiple myeloma, offering significant market potential.
For further insights into TSE:TELO stock, check out TipRanks’ Stock Analysis page.